Deal value includes upfront payment of US$100 million with F2G eligible for … Continue reading “Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia”
Turku, Finland – 18 May 2022: DelSiTech Ltd, the leading silica drug delivery … Continue reading “DelSiTech and Anticancer Bioscience Announce a Collaboration Agreement for the Development of Long-acting Therapies in Oncology”
NEW YORK & PARIS (May 16, 2022) – Apollo (NYSE: APO) and Sofinnova Partners (“Sofinnova”), a … Continue reading “Sofinnova Partners and Apollo form strategic partnership in life sciences”
Shionogi to conduct clinical trials, subsequent registration, and commercialization of olorofim for … Continue reading “Shionogi Co., Ltd. and F2G Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia”
Brighton, United Kingdom – 12 May 2022 – Destiny Pharma (AIM: DEST), a … Continue reading “Destiny Pharma – World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration”
Diepenbeek, Belgium, 12 May 2022 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company … Continue reading “Rejuvenate Biomed appoints life sciences leader Dr. Ajit Shetty as Chair of the Board of Directors to help guide international ambitions”
Inglewood, California, May 12th, 2022 – ImaginAb Inc., a market-leading global biotechnology company … Continue reading “ImaginAb announces a new supply agreement with Invicro to offer clinical doses of CD8 investigational ImmunoPET imaging agent for Immuno-Oncology preclinical and clinical studies”
Novo Holdings today announces it has participated in a $60.5 million oversubscribed … Continue reading “Novo Holdings backs animal health company Invetx”
Ronopterin significantly reduces glutamate levels measured in brain microdialysate from TBI patients, … Continue reading “vasopharm GmbH Announces Brain Glutamate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury”
Antibiotics are used to treat or prevent some types of bacterial infection, … Continue reading “Novo Nordisk Foundation – Researchers mobilise to combat antimicrobial resistance”
Los Angeles, CA, USA, May 5th, 2022 – ImaginAb, Inc., a market leading … Continue reading “ImaginAb Announces New Supply Agreement to Supply Genmab A/S with its Investigational CD8 ImmunoPET Agent”
Munich, Germany, 04 May 2022 – AMSilk GmbH (“AMSilk”), a world leader in … Continue reading “AMSilk appoints Klaus Kjedal as Chief Production Officer and Managing Director”
Utrecht, Netherlands and Boston, Mass., 4th May 2022: Gadeta B.V. (‘Gadeta’), a … Continue reading “Gadeta to Attend Upcoming Business and Investor Conferences”
Lausanne, SWITZERLAND and San Francisco, CA, USA, 4 May 2022 – Asceneuron SA, … Continue reading “Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson’s Disease Therapies”
The leading European central nervous system specialty company expands its operations in … Continue reading “Neuraxpharm pursues growth strategy for business in Switzerland”
Destiny Pharma strengthens Executive Management Team with the appointment of Dr Yuri Martina as Chief Medical Officer Brighton, United Kingdom – … Continue reading “Destiny Pharma appoints Dr Yuri Martina as CMO”
Financing co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch … Continue reading “Engimmune Therapeutics raises CHF 15.5 million in seed financing to develop novel T-cell receptor therapeutics”
Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and … Continue reading “Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer”
03 May 2022, Cambridge, UK: STORM Therapeutics, the biotechnology company focused on the … Continue reading “STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme”
For more information about Optimum Strategic Communications, please get in touch
We'd love to hear from you...
GET IN TOUCH
© Copyright 2022 Optimum Strategic Communications All rights reserved.
The Spice Building
8 Devonshire Square
London
EC2M 4PL
Tel: +44 (0)203 950 9144
Email: contact@optimumcomms.com
